Fuelled by its vision to provide “Access to precision medtech for every patient, globally," Fuelled by its vision to provide “Access to precision medtech for every patient, globally," it is present across 80 countries. With a comprehensive product range covering 52,000 SKUs across 4 key focus areas : advanced surgery, wound care, urology and arthroscopy, it operates across 3 key markets, India, UK and Rest of the World. 1 in 5 surgeries conducted globally, uses a Healthium product as on 31st March 2021. As of Fiscal Year 2021, Healthium Medtech is the largest independent medical devices company in India and 2nd largest in the surgical consumables market in India, the largest non-captive surgical needles manufacturer globally by volume and the 3rd largest company in the urology collection devices market in the UK. Healthium has India’s largest direct sales force amongst independent medical device manufacturers that covers 90% of all districts in India with secondary healthcare facilities with over 40,000 surgeons in 18,000 hospitals as on 31st March,2021. Healthium is driving global Innovation by focusing on R & D. Since fiscal year 2018, it has sold 30 new products including its patented arthroscopy portfolio, 1st barbed suture with a triangular stopper & anti-microbial glove, Trushield. It holds 35 patents in U.S, Europe and India and 29 pending patent applications (including CareNow), as on 31st March,2021 . It has 8 high precision, integrated and scaled manufacturing facilities with global certifications and approvals like US FDA, C.E and ISO. DISCLAIMER:
“Healthium Medtech Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus (“DRHP”) with the Securities and Exchange Board of India. The DRHP is available on the website of the SEBI at www.sebi.gov.in as well as on the websites of the book running lead managers, ICICI Securities Limited, CLSA India Private Limited, Credit Suisse Securities (India) Private Limited and Nomura Financial Advisory and Securities (India) Private Limited, at www.icicisecurities.com, www.india.clsa.com, www.credit-suisse.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively, and the websites of the stock exchange(s) at www.bseindia.com and www.nseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" of the RHP / Prospectus, when available. Potential investors should not rely on the DRHP for any investment decision.”
